CHMP recommends extension of Isentress indication for HIV - 22-Oct-2012
The CHMP has recommended a change to the indication for Isentress (raltegravir), from Merck., which is now indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 2 years.
Related News
EC approve new strength Prezista (J&J Janssen Cilag) for AIDS patients
ViiV healthCare files dolutegravir for HIV treatment in EU, US and Canada
FDA updates prescribing information for Edurant (Tibotec) for AIDS patients
FDA approves Stribild ( Gilead Sciences) for treatment of HIV-1 Infection
Vacc-4x (Bionor Pharma) in Phase III trial with Revlimid(Celgene)for HIV treatment
Positive results from Phase III study of Isentress (Merck Inc) for HIV-1 patients
Success in Phase III SINGLE trial of Dolutegravir
Gilead Sciences files cobicistat"booster" for AIDS drugs
Related HIV/AIDS Information
HIV/AIDS Clinical Guidelines
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
AidsinfoBritish HIV Association guidelines for the treatment of TB/HIV coinfection 2011
British HIV AssociationHIV/AIDS Clinical Trials
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Clinicaltrials.gov 01 March 2013Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
Clinicaltrials.gov 22 February 2013HIV/AIDS Medical Journal Abstracts
Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials
HIV Medicine 22 November 2012HIV-1 co-receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic
HIV Medicine 22 November 2012HIV/AIDS Medical Apps
CCO HIV inPractice
Free
HIV iChart
Free
Advert for Healthcare Professionals only